Santhera Pharmaceuticals Holding AG (SWX:SANN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 163.08M |
| Revenue (ttm) | 49.02M |
| Net Income (ttm) | -65.54M |
| Shares Out | 13.37M |
| EPS (ttm) | -5.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 45,164 |
| Average Volume | 55,878 |
| Open | 12.30 |
| Previous Close | 12.40 |
| Day's Range | 12.00 - 12.42 |
| 52-Week Range | 7.81 - 17.76 |
| Beta | -0.74 |
| RSI | 63.77 |
| Earnings Date | Dec 12, 2025 |
About SWX:SANN
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG ... [Read more]
Financial Performance
Financial StatementsNews
Half Year 2025 Santhera Pharmaceuticals Holding AG Analyst Briefing Transcript
Half Year 2025 Santhera Pharmaceuticals Holding AG Analyst Briefing Transcript
Santhera Partners With Biomedica To Distribute Agamree In Russia
(RTTNews) - Santhera Pharmaceuticals Holding AG (SPHDF, SANN.SW), on Thursday, announced an agreement with Biomedica Group Ltd. to distribute Agamree or vamorolone in Russia for treating Duchenne musc...
Health Canada Approves Santhera's AGAMREE For Duchenne Muscular Dystrophy
(RTTNews) - Santhera Pharmaceuticals (SANN.SW) announced that it has received approval from Health Canada for AGAMREE (vamorolone) as a treatment for Duchenne muscular dystrophy (DMD) in patients aged...
Santhera Pharmaceuticals Holding AG (SPHDF) Q2 2025 Earnings Call Transcript
Santhera Pharmaceuticals Holding AG (OTCPK:SPHDF) Q2 2025 Earnings Call September 23, 2025 8:00 AM EDT Company Participants Catherine Isted - Chief Financial Officer Shabir Hasham - Chief Medical Offi...
Santhera Pharmaceuticals Holding AG 2025 Q2 - Results - Earnings Call Presentation
Santhera Pharma Stock Down On Wider H1 Loss; Is AGAMREE On Track?
(RTTNews) - Santhera Pharmaceuticals Holding AG (SPHDF.OB, SANN.SW), a Swiss firm, reported Tuesday a wider loss in its first half mainly due to a $25 million milestone payable, despite improved reven...
Santhera Enters into Agreement with Ikris Pharma Network for the Distribution of AGAMREE® (Vamorolone) in India
Pratteln, Switzerland , 29 August , 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Ikris Pharma Network (Ikris) to manage the distribution of AGAMREE®...
Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries
Pratteln, Switzerland , 19 August , 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the ...
Santhera Pharmaceuticals reports FY results
Santhera Pharmaceuticals reports FY results
Santhera Pharmaceuticals Provides Update on Royalty Agreement for AGAMREE® (Vamorolone) and Warrants held by Idorsia
Pratteln, Switzerland, January 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces that Idorsia Pharmaceuticals has entered into a royalty monetization agreement with the R-Bridge Healthcare Fun...
Santhera Enters into Supply and Distribution Agreement for AGAMREE® (Vamorolone) with Clinigen Group
Pratteln, Switzerland, January 6, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® (vam...
Santhera Announces Approval from China's NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
China's National Medical Products Administration (NMPA) approved AGAMREE® for the treatment of Duchenne muscular dystrophy in patients aged 4 years and older This approval makes AGAMREE the first and ...
Santhera Pharmaceuticals reports 1H results
Santhera Enters into an Exclusive Distribution Agreement with GENESIS Pharma for AGAMREE® (Vamorolone) in Central and Eastern Europe
Pratteln, Switzerland, September 10, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive distribution agreement with GENESIS Pharma for AGAMREE® (vamorolone) for the trea...